- Home
- HRMY
as 02-21-2025 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Upcoming Earnings Alert:
Get ready for potential market movements as Harmony Biosciences Holdings Inc. HRMY prepares to release earnings report on 25 Feb 2025.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 2.2B | IPO Year: | 2020 |
| Target Price: | $54.38 | AVG Volume (30 days): | 557.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.11 | EPS Growth: | -14.80 |
| 52 Week Low/High: | $28.14 - $41.61 | Next Earning Date: | 02-25-2025 |
| Revenue: | $681,879,000 | Revenue Growth: | 25.83% |
| Revenue Growth (this year): | 25.11% | Revenue Growth (next year): | 19.19% |
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 24 '25 | Sell | $37.61 | 14,754 | $551,575.01 | 0 | |
| Kapadia Sandip | HRMY | CHIEF FINANCIAL OFFICER | Jan 24 '25 | Sell | $38.05 | 1,775 | $67,547.27 | 0 | |
| Dayno Jeffrey M. | HRMY | PRESIDENT, CEO | Jan 21 '25 | Sell | $40.13 | 19,293 | $774,245.45 | 0 | |
| Kapadia Sandip | HRMY | CHIEF FINANCIAL OFFICER | Jan 21 '25 | Sell | $40.18 | 25,000 | $1,004,597.50 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 16 '25 | Sell | $38.71 | 30,598 | $1,147,715.34 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 15 '25 | Sell | $37.01 | 10,507 | $388,840.95 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 13 '25 | Sell | $37.04 | 7,180 | $265,946.48 | 0 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Deutsche Bank Adjusts Harmony Biosciences Price Target to $52 From $55, Maintains Buy Rating
MT Newswires
2 days ago
Mizuho Adjusts Price Target on Harmony Biosciences to $42 From $52, Keeps Outperform Rating
Investor's Business Daily
3 days ago
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug
Benzinga
3 days ago
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
MT Newswires
3 days ago
Harmony Biosciences Receives US FDA's Refusal to File Letter Related to Application for Pitolisant in Idiopathic Hypersomnia
Business Wire
3 days ago
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
Argus Research
4 days ago
HRMY: Raising target price to $41.00
Business Wire
4 days ago
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.